Page 3 - Scare Med News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Scare med. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Scare Med Today - Breaking & Trending Today

EFFORT Protein trial: questions remain – Authors' reply

EFFORT Protein trial: questions remain – Authors' reply
thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.

United States , G Jan Zijlstra , American Society For Parenteral , Society Of Critical Care Medicine , Scare Med , Critical Care Medicine , American Society , Enteral Nutrition ,

The Lancet Commission to reduce the global burden of sudden cardiac death: a call for multidisciplinary action

The Lancet Commission to reduce the global burden of sudden cardiac death: a call for multidisciplinary action
thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.

Noord Holland , Noord Brabant , South Africa , United Kingdom , New York , United States , New Zealand , Schleswig Holstein , Uttar Pradesh , France General , Nordrhein Westfalen , Jammu And Kashmir , South Korea , Wei Ming , Andhra Pradesh , Eastern Cape , Health Administration , Al Qalyubiyah , Cardiovasc Diabetol , Ben Khelil , Sithy Athiya Munavarah , Hinkle Jr , Ben Ahmed , Cardiovasc Disord , Acta Anaesthesiol Scand , Perazzolo Marra ,

KRAS(G12D) drives lepidic adenocarcinoma through stem-cell reprogramming

Many cancers originate from stem or progenitor cells hijacked by somatic mutations that drive replication, exemplified by adenomatous transformation of pulmonary alveolar epithelial type II (AT2) cells1. Here we demonstrate a different scenario: expression of KRAS(G12D) in differentiated AT1 cells reprograms them slowly and asynchronously back into AT2 stem cells that go on to generate indolent tumours. Like human lepidic adenocarcinoma, the tumour cells slowly spread along alveolar walls in a non-destructive manner and have low ERK activity. We find that AT1 and AT2 cells act as distinct cells of origin and manifest divergent responses to concomitant WNT activation and KRAS(G12D) induction, which accelerates AT2-derived but inhibits AT1-derived adenoma proliferation. Augmentation of ERK activity in KRAS(G12D)-induced AT1 cells increases transformation efficiency, proliferation and progression from lepidic to mixed tumour histology. Overall, we have identified a new cell of or ....

United States , Cancer Biol , American Thoracic , European Respiratory Society , Single Cell Wnt , Stem Cell , Cell Biol , Scare Med , Cancer Staging Project , Lung Cancer , Lung Cancer Res , International Association , Lung Cancer Pathology , Genes Dev , Nucleic Acids Res ,